Alessandro M. Minisini
Udine, 33100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications
Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?
Journal: Cancers
Published: May 04, 2026
Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.
Journal: Cancers
Published: April 16, 2026
Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma.
Journal: Cancers
Published: April 14, 2026
New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.
Journal: Cancers
Published: April 14, 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 13, 2026
High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors.
Journal: Journal of translational medicine
Published: October 02, 2025
Development of a Machine Learning Model for Predicting Treatment-Related Amenorrhea in Young Women with Breast Cancer.
Journal: Bioengineering (Basel, Switzerland)
Published: September 30, 2025
Prognostic and predictive value of HRD in early triple negative breast cancer (TNBC).
Journal: Critical reviews in oncology/hematology
Published: August 07, 2025
Postoperative Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer With GammaPod Technology: A Phase 2 Clinical Trial.
Journal: International journal of radiation oncology, biology, physics
Published: June 27, 2025
Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study.
Journal: Breast (Edinburgh, Scotland)
Published: June 24, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 05, 2025
Are There High-Risk Prognostic Factors for Isolated Locoregional Recurrence in Patients With Early-Stage Breast Cancer Treated With Mastectomy Without Adjuvant Radiation Therapy?
Journal: Advances in radiation oncology
Published: May 24, 2025
Last Updated: 09/26/2026